Investera med insikt - Data visar vägen!

Bevaka (0)

Xvivo Perfusion


Mid Cap


Health Care

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden.



Länk till dynamisk (zoombar) graf för större skärmar

Nuvarande och kommande formation

MA Rank

Free stock photo of 4k wallpaper, bridge, daylight
Photo by Markus Spiske on Pexels

Välkommen till Indicatum!

Vi bygger vår nya plattform och kan tyvärr inte ta emot nyregistreringar just nu, men registrera din e-postadress nedan så får du en notis när vi lanserar tjänsten.

Vi ser fram emot att höra från dig!

Vi spammar inte!
Din email kommer endast att användas för att meddela dig när plattformen lanseras

Rulla till toppen